BRIEF—Erytech Pharma opens new US facility

Erytech Pharma has opened a new GMP manufacturing facility in New Jersey, USA, to support production capacity needs for its lead candidate Graspa (eryaspase), which is in Phase III testing for pancreatic cancer as a second-line option.

The facility will begin manufacturing eryaspase in the fourth quarter of 2019 to ensure supply for US participants in the Trybeca-1 trial.

The firm plans to use the facility to meet commercial demand in the event of approval in the USA.